Basic Information
| LncRNA/CircRNA Name | lncRNA-ATB |
| Synonyms | LOC109207222 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | cell lines (A549, H1975, A549/CDDP) |
| Expression Pattern | differential expressed |
| Function Description | lncRNA-ATB is dramatically up-regulated in cisplatin-resistant LUAD cell lines, and that lncRNA-ATB facilitates cell survival by targeting the miR-200a/?-catenin pathway in these cells. |
| Pubmed ID | 32256108 |
| Year | 2020 |
| Title | LncRNA-ATB Promotes Cisplatin Resistance in Lung Adenocarcinoma Cells by Targeting the miR-200a/?-Catenin Pathway |
External Links
| Links for lncRNA-ATB | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |